ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.46 USD
0.00 (0.61%)
Updated May 2, 2024 03:58 PM ET
After-Market: $0.46 0.00 (0.02%) 7:46 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
ASLAN Pharmaceuticals Ltd. [ASLN]
Reports for Purchase
Showing records 21 - 40 ( 99 total )
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
More Than Just Skin Deep; Initiating Buy, $15 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Phase 2a Alopecia Areata Trial Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
R&D Day Highlights Unmet Need in Alopecia Areata; Adjusting PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Phase 2 Program in Alopecia Areata Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
TREK-AD Study Completes Enrollment; Financing Completed; Reiterate Buy; Adjusting PT to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Partnership Inked for Manufacturing of High Concentration Eblasakimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
TREK-DX Study Starts Screening Dupilumab-Experienced AD Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
New Data in Atopic Dermatitis Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Clinical Program in Dupilumab-Experienced Atopic Dermatitis Commences; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
New Biomarker and Patient Outcome Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
2Q22 Financial Results Reported; Reiterate Buy; Modulating PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
KOL Webinar Delineates Unmet Needs in Atopic Dermatitis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Neuronal Itch Mechanisms and Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Company: ASLAN Pharmaceuticals Ltd.
Industry: Medical - Biomedical and Genetics
Nervous Markets, But We See Outperforming Names: H.C. Wainwright''s 2022 Top Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department